A Glimpse Into The Expert Outlook On Avidity Biosciences Through 6 Analysts
Portfolio Pulse from Benzinga Insights
In the last three months, 6 analysts have published ratings on Avidity Biosciences (NASDAQ:RNA), with 5 being bullish and 1 somewhat bullish. The average 12-month price target is $39.67, up 15.55% from the previous $34.33. Analysts have maintained or announced 'Buy' and 'Overweight' ratings, with price targets ranging from $33.00 to $60.00. Financially, Avidity Biosciences has shown a 58.67% revenue growth rate but faces challenges with negative net margins, ROE, and ROA.
June 10, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avidity Biosciences (NASDAQ:RNA) has received predominantly bullish ratings from analysts, with an average 12-month price target of $39.67, up 15.55% from the previous target. Financially, the company has shown strong revenue growth but faces challenges with negative net margins, ROE, and ROA.
The predominantly bullish ratings and increased price target suggest positive short-term sentiment among analysts. However, financial challenges such as negative net margins, ROE, and ROA may temper the overall impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100